Under the deal, Ionetix will supply astatine-211 to PMI in support of the firm's clinical development of targeted alpha therapies. PMI is currently developing PMI21, an astatine-211-labeled inhibitor of prostate-specific membrane antigen (PSMA). Clinical trials for PMI21 are expected to begin later this year in patients with metastatic prostate cancer, according to the firms.
Ionetix plans to commission a new facility this year in Lansing, MI, dedicated to the manufacturing and distribution of alpha-emitting radioisotopes, including astatine-211.
Copyright © 2022 AuntMinnie.com